

November 13, 2025

BSE Limited

P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Scrip Code: 543904

Symbol: MANKIND

Dear Sir/ Madam,

Subject: Intimation of participation in the Investor Conference

Pursuant to Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find below proposed schedule of participation in Investor Conference by officials of the Company:

Date	Name of Event	City	Meeting Type
November 18, 2025	Aventus Spark INDX 2025- The New Code for India's Growth	Mumbai	One on One and Group Meeting

Please note that no unpublished price sensitive information will be shared at the aforesaid Investor Conference.

The schedule of the above mentioned Investor Conference is subject to change due to exigencies on either side.

The intimation of participation in the Investor Conference is also being uploaded on the website of the company i.e. www.mankindpharma.com.

This is for your information and records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

Hitesh Kumar Jain
Company Secretary &
Compliance Officer

MANKIND PHARMA LIMITED

Regd. Office : 208, Okhla Ind. Estate, Phase - 3, New Delhi-110020 • Ph. : 011-46846700, 47476600
CIN No. L74899DL1991 PLC044843 • E-mail : contact@mankindpharma.com • www.mankindpharma.com